thalidomide has been researched along with Thalassemia in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Thalassemia: A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia." | 8.02 | Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021) |
| "To assess the efficacy and safety of thalidomide in children with transfusion-dependent thalassemia." | 4.02 | Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia. ( Chandra, J; Goel, M; Parakh, N; Pemde, H; Sharma, S; Singh, N, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, J | 2 |
| Khera, S | 1 |
| Kandasamy, D | 1 |
| Vidyasagar, S | 1 |
| Bolanthakodi, N | 1 |
| Vaidya, AK | 1 |
| Prethika, PA | 1 |
| Mohan, G | 1 |
| Shastry, S | 1 |
| Parakh, N | 1 |
| Singh, N | 1 |
| Sharma, S | 1 |
| Goel, M | 1 |
| Pemde, H | 1 |
| Kalra, M | 1 |
| Khanna, VK | 1 |
| Trehan, A | 1 |
| Mahajan, A | 1 |
| Fozza, C | 1 |
| Pardini, S | 1 |
| Giannico, DB | 1 |
| Targhetta, C | 1 |
| Di Tucci, AA | 1 |
| Dessalvi, P | 1 |
| Angelucci, E | 1 |
| Dore, F | 1 |
| Ricchi, P | 1 |
| Costantini, S | 1 |
| Spasiano, A | 1 |
| De Dominicis, G | 1 |
| Di Matola, T | 1 |
| Cinque, P | 1 |
| Ammirabile, M | 1 |
| Marsella, M | 1 |
| Filosa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia: a Quasi Randomized Control Trial in a Tertiary Care Hospital in Bangladesh[NCT06098014] | Phase 3 | 60 participants (Anticipated) | Interventional | 2023-03-08 | Recruiting | ||
| Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia Patients of Pakistan[NCT03651102] | Phase 2/Phase 3 | 654 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for thalidomide and Thalassemia
| Article | Year |
|---|---|
Safety: A Primary Concern in Thalidomide Use in Thalassemia: Reply.
Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide | 2021 |
Safety: A Primary Concern in Thalidomide Use in Thalassemia.
Topics: beta-Thalassemia; Humans; Thalassemia; Thalidomide | 2021 |
Unveiling the masked native blood group following thalidomide therapy in a thalassemia patient: A 5 WHY analysis approach.
Topics: Adult; Blood Group Antigens; Blood Grouping and Crossmatching; Female; Humans; Pregnancy; Rh-Hr Bloo | 2022 |
Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia.
Topics: Adolescent; beta-Thalassemia; Child; Hemoglobins; Humans; Prospective Studies; Thalassemia; Thalidom | 2021 |
Thalidomide in Transfusion Dependent Thalassemia: Hope or Hype.
Topics: Blood Transfusion; Child; Humans; Immunosuppressive Agents; Male; Thalassemia; Thalidomide; Treatmen | 2017 |
Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis.
Topics: Aged; Anemia, Hemolytic; Antibodies, Monoclonal, Murine-Derived; Blood Transfusion; Female; Hemolysi | 2015 |
The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia.
Topics: Antisickling Agents; Blood Transfusion; Bone Marrow; Drug Administration Schedule; Female; Fetal Hem | 2016 |